1|Page
NAMS Menopause Certification Test Bank Exam 2026-2027
BANK QUESTIONS WITH DETAILED VERIFIED
ANSWERS EXAM QUESTIONS WILL COME FROM
HERE (100% Latest Already Graded A+
1. A 52-year-old woman presents with hot flashes, night sweats, and
vaginal dryness. She has a history of breast cancer treated with
tamoxifen five years ago. Which of the following is the most
appropriate initial management strategy for her vasomotor symptoms?
A) Systemic estrogen therapy
B) Vaginal estrogen therapy
C) Cognitive behavioral therapy and nonhormonal pharmacologic
options
D) Testosterone therapy
Answer: C
Explanation: In a patient with a history of breast cancer, systemic
estrogen is generally contraindicated. Vaginal estrogen is considered for
genitourinary symptoms but has limited systemic absorption and is not
the primary treatment for vasomotor symptoms. Cognitive behavioral
therapy and nonhormonal options such as selective serotonin reuptake
,2|Page
inhibitors or gabapentin are recommended for vasomotor symptom
management in breast cancer survivors. Testosterone is not approved
for vasomotor symptoms and lacks robust evidence.
2. Which statement best describes the role of menopausal hormone
therapy in primary prevention of chronic conditions?
A) Hormone therapy is recommended for primary prevention of
coronary heart disease.
B) Hormone therapy reduces the risk of dementia when started in early
menopause.
C) Hormone therapy is not indicated for primary prevention of any
chronic disease.
D) Hormone therapy prevents osteoporotic fractures but increases the
risk of venous thromboembolism.
Answer: C
Explanation: The US Preventive Services Task Force and other guidelines
advise against the use of hormone therapy for primary prevention of
chronic conditions, including cardiovascular disease and dementia.
While hormone therapy does reduce fracture risk and may have a
favorable risk-benefit profile for symptom management, it is not
recommended solely for disease prevention due to associated risks such
as venous thromboembolism and stroke.
3. A 55-year-old woman on oral conjugated equine estrogens 0.625 mg
daily and medroxyprogesterone acetate 2.5 mg daily reports breast
,3|Page
tenderness and irregular bleeding. What is the most appropriate next
step?
A) Discontinue both medications immediately.
B) Switch to a lower-dose formulation.
C) Perform transvaginal ultrasound and endometrial biopsy if indicated.
D) Increase the progestin dose.
Answer: C
Explanation: Irregular bleeding in a woman on continuous combined
hormone therapy requires evaluation to rule out endometrial
pathology, especially if bleeding persists beyond the first six months of
therapy. Transvaginal ultrasound to assess endometrial thickness is the
initial step, and biopsy is indicated if thickness is >4-5 mm or if bleeding
is unexplained.
4. The North American Menopause Society recommends which of the
following as first-line therapy for genitourinary syndrome of
menopause?
A) Systemic estrogen therapy
B) Vaginal lubricants and moisturizers
C) Vaginal estrogen therapy
D) Ospemifene
Answer: B
, 4|Page
Explanation: NAMS recommends vaginal lubricants and moisturizers as
first-line management for mild to moderate genitourinary symptoms.
Vaginal estrogen and ospemifene are reserved for moderate to severe
symptoms or when nonhormonal options are insufficient. Systemic
estrogen may not adequately treat localized vaginal atrophy.
5. A 48-year-old woman with premature ovarian insufficiency desires
hormone therapy. Which regimen is most appropriate?
A) Oral contraceptives until age 50, then transition to hormone therapy
B) Hormone therapy until the average age of natural menopause
C) No hormone therapy due to cardiovascular risk
D) Testosterone alone
Answer: B
Explanation: Women with premature ovarian insufficiency benefit from
hormone therapy to reduce risks of osteoporosis and cardiovascular
disease. Treatment should continue until the average age of natural
menopause, approximately 51-52 years, using doses similar to standard
hormone therapy. Oral contraceptives may be used but hormone
therapy is generally preferred for bone and cardiovascular protection.
6. Which of the following is a contraindication to systemic menopausal
hormone therapy?
A) History of deep vein thrombosis
B) History of endometriosis
NAMS Menopause Certification Test Bank Exam 2026-2027
BANK QUESTIONS WITH DETAILED VERIFIED
ANSWERS EXAM QUESTIONS WILL COME FROM
HERE (100% Latest Already Graded A+
1. A 52-year-old woman presents with hot flashes, night sweats, and
vaginal dryness. She has a history of breast cancer treated with
tamoxifen five years ago. Which of the following is the most
appropriate initial management strategy for her vasomotor symptoms?
A) Systemic estrogen therapy
B) Vaginal estrogen therapy
C) Cognitive behavioral therapy and nonhormonal pharmacologic
options
D) Testosterone therapy
Answer: C
Explanation: In a patient with a history of breast cancer, systemic
estrogen is generally contraindicated. Vaginal estrogen is considered for
genitourinary symptoms but has limited systemic absorption and is not
the primary treatment for vasomotor symptoms. Cognitive behavioral
therapy and nonhormonal options such as selective serotonin reuptake
,2|Page
inhibitors or gabapentin are recommended for vasomotor symptom
management in breast cancer survivors. Testosterone is not approved
for vasomotor symptoms and lacks robust evidence.
2. Which statement best describes the role of menopausal hormone
therapy in primary prevention of chronic conditions?
A) Hormone therapy is recommended for primary prevention of
coronary heart disease.
B) Hormone therapy reduces the risk of dementia when started in early
menopause.
C) Hormone therapy is not indicated for primary prevention of any
chronic disease.
D) Hormone therapy prevents osteoporotic fractures but increases the
risk of venous thromboembolism.
Answer: C
Explanation: The US Preventive Services Task Force and other guidelines
advise against the use of hormone therapy for primary prevention of
chronic conditions, including cardiovascular disease and dementia.
While hormone therapy does reduce fracture risk and may have a
favorable risk-benefit profile for symptom management, it is not
recommended solely for disease prevention due to associated risks such
as venous thromboembolism and stroke.
3. A 55-year-old woman on oral conjugated equine estrogens 0.625 mg
daily and medroxyprogesterone acetate 2.5 mg daily reports breast
,3|Page
tenderness and irregular bleeding. What is the most appropriate next
step?
A) Discontinue both medications immediately.
B) Switch to a lower-dose formulation.
C) Perform transvaginal ultrasound and endometrial biopsy if indicated.
D) Increase the progestin dose.
Answer: C
Explanation: Irregular bleeding in a woman on continuous combined
hormone therapy requires evaluation to rule out endometrial
pathology, especially if bleeding persists beyond the first six months of
therapy. Transvaginal ultrasound to assess endometrial thickness is the
initial step, and biopsy is indicated if thickness is >4-5 mm or if bleeding
is unexplained.
4. The North American Menopause Society recommends which of the
following as first-line therapy for genitourinary syndrome of
menopause?
A) Systemic estrogen therapy
B) Vaginal lubricants and moisturizers
C) Vaginal estrogen therapy
D) Ospemifene
Answer: B
, 4|Page
Explanation: NAMS recommends vaginal lubricants and moisturizers as
first-line management for mild to moderate genitourinary symptoms.
Vaginal estrogen and ospemifene are reserved for moderate to severe
symptoms or when nonhormonal options are insufficient. Systemic
estrogen may not adequately treat localized vaginal atrophy.
5. A 48-year-old woman with premature ovarian insufficiency desires
hormone therapy. Which regimen is most appropriate?
A) Oral contraceptives until age 50, then transition to hormone therapy
B) Hormone therapy until the average age of natural menopause
C) No hormone therapy due to cardiovascular risk
D) Testosterone alone
Answer: B
Explanation: Women with premature ovarian insufficiency benefit from
hormone therapy to reduce risks of osteoporosis and cardiovascular
disease. Treatment should continue until the average age of natural
menopause, approximately 51-52 years, using doses similar to standard
hormone therapy. Oral contraceptives may be used but hormone
therapy is generally preferred for bone and cardiovascular protection.
6. Which of the following is a contraindication to systemic menopausal
hormone therapy?
A) History of deep vein thrombosis
B) History of endometriosis
